Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
No other corporate actions details are available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback